International Journal of Pharmacognosy and Herbal Drug Technology (IJPHDT)
ISSN: 3049-1630, Vol.02, Issue No. 08, 2025 (pp.79-94)
AKT PUBLICATION
ORIGINAL ARTICLE
https://www.aktpublication.com/index.php/ijphdt

Ethnopharmacology and Pharmacognosy: Intersections in The Search for Novel Therapeutic Agents

Aarushi Pandey[1], Aman Kumar Singh[1], Samridhi Jayant[1], Adarsh Singh[1], Farah Deeba[1*]
[1]Sharda University, Plot No. 32,34, Knowledge Park-III, Greater Noida, Ruhallapur, Uttar Pradesh 201310
***Corresponding Author E-mail: farahdeeba.r@gmail.com**

ABSTRACT

Natural products have been the growing source of new therapeutic agents and the fields of ethnopharmacology and pharmacognosy overlap greatly. Ethnopharmacology is the record of traditional knowledge and medicinal practices and leads researchers to plants and compounds that have possible bioactivity. This is complemented by pharmacognosy which involves isolation, characterization, and assessment of these bioactive compounds by conducting stringent preclinical studies, especially animal models. In this review, the authors have synthesized the most important results of studies conducted on animals, mentioning, in particular, the compounds of 6-hederin of Nigella sativa, and curcumin of Curcuma longa, which have anticancer, anti-inflammatory and immunomodulatory activity. The synthesis of the disciplines provides an improvement to drug discovery by incorporating cultural relevance and scientific validation and focuses on sustainability as well as effectiveness. Issues like standardization, ethical issues and regulatory barriers are critically addressed. Finally, the future opportunities are presented, including the standardized approaches, interdisciplinary approaches, and ethical frameworks, to get the best out of natural products as therapeutic agents. Such review highlights the significance of preparing a bridge between the traditional knowledge and contemporary pharmacological science to promote the creation of effective and sustainable therapeutics.

Key Words:

Ethnopharmacology, Pharmacognosy, Natural Products, Bioactive Compounds, Animal Models, α-Hederin, Curcumin, Drug Discovery

Article History:

Received April 21, 2025

Revised June 28, 2025

Accepted July 12, 2025

Published Aug. 20, 2025

DOI: https://doi.org/10.64063/30491630.vol.2.issue8.7

1. INTRODUCTION

Identification of new therapeutic agents is one of the most crucial goals in contemporary pharmaceutical research due to the continuously growing burden of chronic diseases, cancer, infectious diseases, and inflammatory disorders in the world[1]. Traditionally, the mainstay of medicine has been natural products that are obtained as secondary metabolites of plants, animals and microorganisms, which together comprise a rich source of bioactive agents that have been used to develop modern drugs[2]. As an example, we can mention paclitaxel, a chemical compound produced by Taxus brevifolia, and artemisinin, a compound produced by Artemisia annua that has enormous therapeutic potential inherent in nature.

Figure 1: Pharmacognosy: The study of drugs derived from natural sources like plants, animals, and microorganisms[3].

1.1. Background information and context.

In this context, the concepts of ethnopharmacology and pharmacognosy arise as the complementary sciences. Ethnopharmacology studies the use of natural products in folk and traditional medicine and records knowledge that has frequently been passed orally down through the generations[4]. Such records play a key role in the discovery of therapeutically useful plants and animals and in establishing the context and preparation and cultural importance of these medicines. Pharmacognosy, however, deals with the science of natural products, their chemical constituents, bioactive compounds, their action and pharmacological properties[5]. Pharmacognosy confirms the therapeutic potential of these substances and gives mechanistic information that is invaluable in the modern drug development by using stringent methods like chromatography, spectroscopy and preclinical animal studies[6].

The overlap of these fields closes the gap between traditional healing and modern pharmacology and provides an orderly procedure of identifying and developing new therapeutic agents. The combination of ethnopharmacological knowledge and pharmacogenetic validation will allow researchers to improve the effectiveness of drug discovery and guarantee cultural appropriateness, sustainability and scientific quality.

1.2. Objectives of the Review

- To examine the methodologies employed in ethnopharmacological and pharmacognostic research.
- To highlight key findings from animal-based preclinical studies on bioactive compounds.
- To critically assess the strengths and limitations of current integrative approaches.
- To discuss implications and future directions for drug discovery using natural products.

1.3. Importance of the Topic

The study of the confluence between ethnopharmacology and pharmacognosy is crucial to the future of modern therapeutics. This integrative strategy not only confirms centuries-old traditional knowledge, but also speeds the identification of bioactive compounds that can be used as the lead molecules in drug development[7]. The integration of cultural knowledge and scientific methods will enable the researchers to create effective, safe, and sustainable therapeutic agents. In addition, the study highlights the relevance of animal-based preclinical models to assess efficacy, safety and mechanism of action prior to possible clinical translation[8]. In a time when natural products remain

an invaluable source of new drugs, this intersection and its study and exploitation is paramount to contemporary pharmacology, and the worldwide healthcare industry.

2. ETHNOPHARMACOLOGY: BRIDGING TRADITION AND MODERN SCIENCE

Ethnopharmacology can be viewed as a crucial point of intersection between folk medicine and modern scientific research with the role of connecting millennia-old medicine and pharmacological verification[9]. Through the systematic documentation of the indigenous knowledge, especially on the uses of plants and animals in the traditional healing systems, researchers can discover bioactive compounds that can be the core of new therapeutics. This dual purpose does not only preserve the cultural heritage but also speeds up drug discovery because it gives a starting point based on empirically tested remedies.

2.1. Methodologies in Ethnopharmacological Research

Ethnopharmacology research involves multidisciplinary research incorporating anthropological, botanical, chemical and pharmacological techniques. The basis is ethnobotanical surveys, in which the researchers directly interact with the indigenous populations to record their medicines, mode of preparation, and local knowledge about the use of a plant or an animal. This is usually done through structured interviews, focus groups and participant observation, which can be used to put the therapeutic rationale behind each remedy into context[10].

After collection of specimens, phytochemical analysis is required in isolating and identifying bioactive compounds. To characterize the chemical constituents, solvent extraction, thin layer and high-performance liquid chromatography, and modern spectroscopic methods, including NMR and mass spectrometry, are used. Such analyses make sure that pharmacologically interesting compounds are scientifically identifiable and reproducible.

After isolation, the pharmacological testing is performed to determine biological activity. The properties investigated using both in vitro and in vivo assays include cytotoxicity, antimicrobial, anti-inflammatory, and anticancer activity. Notably, toxicological research is carried out in animal models to determine the safety of these bioactive compounds both in acute and chronic toxicity. Lastly, ethnopharmacological validation entails matching of traditional therapeutic claims with scientific results, to determine whether or not traditional knowledge agrees with the experimental results. These approaches, combine to form a comprehensive system that enhances the scientific basis of folk medicine.

2.2. Case Study: Nigella sativa and α-Hederin

Nigella sativa (black cumin) is one of the numerous plants investigated in ethnopharmacological research, however, it is distinguished by its long use history in the Middle East, South Asia, and Africa traditional medicine systems[11]. N. sativa has drawn a lot of scientific interest due to its pharmacological profile that includes anti-inflammatory, antimicrobial, and immunomodulating properties traditionally utilized in its use. Modern research has discovered a number of active ingredients, the most prominent of which are thymoquinone, nigellone, and alpha-hederin, which are all involved in its therapeutic value.

a) α-Hederin: Structure and Mechanism of Action

α-Hederin is a pentacyclic triterpene saponin isolated from the seeds of N. sativa. Studies have demonstrated its anticancer properties, particularly its ability to induce apoptosis in cancer cells and inhibit tumor growth in animal models. For instance, research has shown that α-hederin induces apoptosis in the SKOV-3 ovarian cancer cell line through mitochondrial-mediated pathways. The chemical structure of α-hederin comprises a hederagenin aglycone moiety attached to a sugar chain, contributing to its bioactivity. Its mechanism of action involves the disruption of mitochondrial membrane potential, activation of caspases, and DNA fragmentation, leading to programmed cell death.

b) In Vivo Studies

Additional support of the therapeutic potential of α-hederin is found in animal studies. Verified in vivo cancer models have shown that α-hederin has been able to cause significant tumor shrinkage, decrease the metastatic potential, and increase survival of the treated cancer. In addition, there is some evidence that α-hederin could be used synergistically with conventional chemotherapeutic agents, enhancing their cytotoxicity, and, possibly, reducing the dose and side effects. The results support the translational potential of the bioactive constituents of N. sativa in preclinical drug discovery.



Figure 2: (A) Plant of N. sativa, (B) Flower, (C) Capsule or fruit, (D) Seeds[12]

2.3. Strengths and Limitations

The ability of ethnopharmacology to combine traditional and modern science is one of its most important strengths. This method both acknowledges indigenous approaches and puts them through a scientific test, leading to the identification of such compounds as 6-α-hederin which have real therapeutic potential. Moreover, the ethnopharmacology has the advantage of identifying bioactive compounds that might have been missed in randomized screening procedures and the process of discovery becomes more efficient and culture-based. Confirmation of traditional medicine also increases its plausibility and extends its possible use in world medicine[13].

In spite of the mentioned benefits, there are a number of challenges. The problem of standardization is also a major constraint: the differences in the conditions of plant cultivation, harvesting, as well as the preparation methods may lead to the different concentration of the active

substances making it hard to reproduce. There are also ethical issues of the fair use of indigenous knowledge where there is the question of intellectual property rights and sharing of benefits with the local people. Besides, the shift of traditional remedies to accepted drugs is accompanied by regulatory challenges, where the complicated procedures of drug approval tend to stall or impede the translation of the promising results into clinical practice.

2.4. Key Contributions to Ethnopharmacology

To situate the discussion, Table 1 lists major scholarly work in ethnopharmacology and pharmacognosy, emphasizing their methodological contributions and results.

Table 1: Reference Table

Reference	Focus Area	Methods	Key Findings/Contributions
Upadhyay & Thakur (2024)[14]	Ethnopharmacognosy, biotechnological approaches	Literature review; discussion of OMICS-based methodologies	Highlighted the challenges in standardization of medicinal plants and suggested OMICS-based strategies for validation.
Heinrich (2013)[15]	Ethnopharmacology & drug discovery	Ethnobotanical analysis; review of case studies	Emphasized the role of ethnobotanical leads in drug discovery and their transition into pharmacological research.
Heinrich et al. (2017)[16]	Pharmacognosy &phytotherapy	Review of pharmacognostic practices; phytochemical analysis	Provided foundational knowledge on phytotherapyand the characterization of bioactive natural compounds.
Leonti et al. (2020)[17]	Ethnobotany & ethnopharmacology	Comparative ethnobotanical and ecological analysis; historical review	Linked ecological theories to ethnopharmacology, stressing the importance of historical data in understanding cultural use of medicinal plants.
Balogun et al. (2019)[18]	Pharmacognosy: medicinal plants	Experimental phytochemical screening; literature review	Showed the importance of pharmacognosy for the discovery of natural products and their therapeutic relevance.
Delgoda (2016)[19]	Pharmacognosy strategies	Critical review of drug development pipelines; methodological discussion	Outlined applications of pharmacognosy in modern drug development, including screening and validation strategies.

3. PHARMACOGNOSY: FROM ISOLATION TO APPLICATION

Pharmacognosy is an essential part of pharmaceutical sciences that aims to connect the traditional knowledge of natural products with the modern drug discovery and drug development[20]. It is the

science and methodical research of bio-active products of plants, animals, and microorganisms, including their identification, extraction, characterization, and ultimately their utilization in medical environments. Due to the growing concern over safer and more effective drugs, pharmacognosy has proven to be invaluable especially in discovering compounds that could be used as leads towards developing new drugs. Animal studies also complement this field further by offering vital information on the effectiveness, safety and mechanism of action of these drugs prior to the ability to assess them in human clinical trials.



Figure 3: A schematic representation of the common natural products' isolation methods[21].

3.1. Isolation and Characterization of Bioactive Compounds

Pharmacognostic research establishes its roots in the selective isolation and the proper characterization of bioactive molecules of natural origin. This procedure guarantees that the healing qualities of these compounds are not lost, and that the chemical identities of these compounds are well understood. The application of a mixture of modern analysis methods has transformed this field and researchers are able to derive accurate and repeatable results.

Techniques of chromatography like High-Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), and Thin-Layer Chromatography (TLC) are very important in the separation and quantification of various substances in a mixture. The methods offer a way to clean up bioactive molecules to a high level of specificity, so that follow-up pharmacological work is done on well-characterized compounds. Take the case of purification of a bioactive saponin, α-hederin, where HPLC has played a significant role in making the purity and yield of the product high[22].

When compounds have been separated, it is important to elucidate the structure. Advanced spectroscopic techniques such as Nuclear Magnetic Resonance (NMR), Mass Spectrometry (MS), and Infrared (IR) spectroscopy enable in-depth understanding of a molecule in terms of structure, chemical bonding, and functional groups. The methods allow the researcher to verify the molecular structure of the complex compounds, which is important in establishing the structure-activity relationship of the compounds. The NMR analysis of 6, 10, 11-trimethyl-6, 10, 11, 16-tetrahydroxy-9-oxo-16-phenyl-9H-xanthen-9-one 2-acetate or 2-acetate-α-hederin, showed the existence of the hederagenin aglycone structure with sugar moieties, which directly correlates with

its pharmacological action.

Besides the chemical methods, molecular biology has also added to the pharmacognosy. DNA barcoding is an effective way of authenticating species of plants and microorganisms, and therefore a way of certifying the authenticity of raw materials in drug discovery and avoiding misidentification of raw materials. Moreover, when used to study gene expression, gene expression studies provide a way to unravel biosynthetic pathways, insight into how plants and microorganisms naturally make these bioactive molecules. These methods are of specific interest to conservation and industrial scale manufacturing and can open up opportunities to biosynthetically engineer rare compounds.

Case Study: α-Hederin from Nigella sativa

An illustrative example of the role of pharmacognosy in modern drug discovery is the study of α-hederin, a pentacyclic triterpene saponin isolated from the seeds of Nigella sativa (commonly known as black cumin). Using a combination of chromatographic and spectroscopic methods, researchers were able to purify and identify this compound with high accuracy. Structural elucidation confirmed that α-hederin consists of a hederagenin aglycone backbone linked to sugar moieties, which contributes significantly to its pharmacological activity.

In vitro experiments, especially on animal models of colon carcinoma, have shown that α-hederin has the ability to induce apoptosis in cancerous cells and also increase the efficacy of standard chemotherapeutic drugs. These results not only point to the potential of this natural compound as a therapeutic tool, but also to the role of pharmacognostic studies in the development of integrative strategies of cancer treatment. As a standalone therapeutic agent and as a chemo sensitizer, 2-hederin is an example of the type of discoveries that natural product-based drug discovery can bring.

Table 2: Isolation and Characterization Techniques in Pharmacognosy[23]

Technique	Purpose	Application Example
HPLC / GC / TLC	Separation and quantification of compounds	Purification of α-Hederin
NMR / MS / IR	Structural characterization	Identification of hederagenin moiety
DNA Barcoding / Gene Analysis	Species verification and pathway analysis	Confirming N. sativa seed origin

3.2. Preclinical Evaluation: Animal-Based Studies

Preclinical testing is core to pharmacognosy, filling the gap between in vitro laboratory-based studies and clinical trials in humans. After isolation and structural characterization of bioactive compounds, pharmacological activity, toxicity profile and mechanism of action should be confirmed in animal models. These studies offer meaningful translational evidence about safety and efficacy, which can be used by the researchers to foresee the therapeutic effect on humans.

- ✓ **Toxicity Studies**

Toxicity testing is the initial step of preclinical evaluation in order to determine the safety profile of new compounds. The testing of acute, sub-acute, and chronic toxicity is usually conducted in rodents or other pertinent animal models. Such studies aid in the identification of ranges of lethal doses, organ-specific toxicities and any adverse effects that can be experienced with a long-term administration. An example is the rodent models used to determine the no-observed-adverse-effect level (NOAEL) of a bioactive molecule to provide safe dosage guidelines to be used in future efficacy studies. This type of systematic assessment eliminates the occurrence of unexpected risks in human studies.



Figure 4: NOAEL is expressed in the amount of a chemical taken daily per kg body weight[24]

- ✓ **Efficacy Studies**

Once safety profiles have been determined, pharmacognosy research is done to confirm therapeutic efficacy with disease-specific animal models. These experiments recapitulate human physiology so as to determine whether a drug has any significant clinical action. As an example, 1, the saponin 1, 2, 3-trihydroxy-2-methylbarbarin (1,2,3-trihydroxy-2-methylbarbarin) isolated from Hedera helix, has shown excellent tumor regressions in mouse models of colon carcinoma. In addition, its management increased the cytotoxic effects of conventional chemotherapy drugs, which underscores its use as an adjuvant in cancer treatment. Efficacy studies are important to prioritize compounds that should be further developed because they illustrate the therapeutic significance of pharmacognostic findings.

- ✓ **Mechanistic Studies**

Besides toxicity and efficacy studies, mechanistic investigations are key in determining the manner in which natural compounds perform their pharmacological effects. Molecular and cellular signaling pathways, including induction of apoptosis, regulation of immune responses, inhibition of pro-inflammatory cytokines, or enzymatic inhibition can be investigated in-depth using animal models. Still in the case of α-Hederin, mechanistic studies showed that it could activate caspase pathways, induce programmed cell death and regulate immune cell proliferation, thus offering a complete picture of the underlying mechanism of its antitumor properties. These mechanistic understandings not only assist in therapeutic validation, but also direct rational drug design and combination therapies.

3.3. Strengths and Weaknesses of Animal-Based Studies

Animal models offer a number of benefits, such as reliable preclinical information, strong support of efficacy, and the possibility of performing mechanistic studies not possible in vitro. Nevertheless, there are still constraints. Reproducibility may be compromised by the variability in the response of different species, because animals do not necessarily reproduce the human physiological response. Outcomes can be further influenced by environmental factors, by genetic diversity and by strain specific sensitivities. Furthermore, the ethical issues of animal welfare require the use of a strict 3Rs principle of Replacement, Reduction, and Refinement of animal suffering in order to achieve the scientific reliability.

Table 3: Preclinical Evaluation Parameters in Pharmacognosy[25]

Parameter	Purpose	Example with α-Hederin
Toxicity Assessment	Determine safe dosage and adverse effects	Acute and chronic toxicity tests in rodents
Efficacy Testing	Evaluate therapeutic potential	Tumor regression in colon carcinoma models
Mechanistic Studies	Understand molecular pathways of action	Apoptosis induction and caspase activation

Pharmacognosy is the combination of sophisticated chemical, biological and analytical methods to convert natural products to therapeutically useful materials. By means of stringent isolation, characterization and preclinical studies, compounds such as α-Hederin are evidence of the promise of pharmacognostic research in aiding contemporary medicine. Although the strong aspects comprise specific identification and mechanistic understanding, reproducibility, species differences, and ethical adherence are still a challenge, which necessitates the importance of standardized methods in preclinical assessment.

4. INTEGRATIVE APPROACHES: SYNERGY BETWEEN DISCIPLINES

The merger of ethnopharmacology and pharmacognosy is a whole picture in drug discovery. Integrating the traditional knowledge and the strict scientific analysis and evaluation enables researchers to effectively discover and validate new bioactive compounds. This integrative approach does not only hasten the discovery process but also makes therapeutics culturally palatable, sustainable and scientifically sound[26].

4.1. Co-operative Methodologies

Integration means the combination of the merits of the two scientific fields: ethnopharmacology adds the traditional knowledge and ethnobotanical knowledge, whereas pharmacognosy adds sophisticated methods of analysis and preclinical testing.

Some of the Major Methodologies are:

1. **Ethnobotanical Documentation:** Documenting information about how traditional people use it, how it is prepared and dosage.
2. **Phytochemical Isolation & Characterization:** This involves the isolation of bioactive compounds using chromatographic, spectroscopic and molecular methods of documented plants.

3. **Preclinical Animal Studies:** Animal testing of toxicity, efficacy and mechanism of action.
4. **Bioactivity-Guided Fractionation:** Fractionation of extracts and testing their biological activity can be used to relate traditional knowledge to individual bioactive compounds.
5. **Cross-Validation:** The comparison of conventional applications with pharmacological effects as a validation of therapeutic relevance.

Example Studies:

- Traditionally, curcuma longa (turmeric) is used in treating inflammation. Its active ingredient, curcumin, has been confirmed in animal experiments as anti-inflammatory and anticancer.
- Nigella sativa research that integrates traditional indications with pharmacognostic analysis of 0-hederin has shown anticancer and immunomodulatory activity in mouse models.

Table 4: Collaborative Methodologies in Integrative Research[27]

Methodology	Purpose	Example Application
Ethnobotanical Documentation	Capture traditional knowledge and usage	Use of Curcuma longa for inflammation
Phytochemical Isolation	Identify active compounds	Isolation of α-hederin from N. sativa
Preclinical Animal Studies	Evaluate efficacy, toxicity, and mechanism	Tumor regression in colon carcinoma models
Bioactivity-Guided Fractionation	Link traditional use to specific bioactive compounds	Screening plant fractions for cytotoxicity
Cross-Validation	Confirm traditional claims with scientific data	Correlation of turmeric's anti-inflammatory effects

4.2. Strengths and Advantages

The combination of ethnopharmacology with pharmacognosy has several benefits:

- **Increased Discovery:** Traditional knowledge guides researchers to plants and compounds that have a greater chance of bioactivity.
- **Cultural Relevance:** The indigenous practice-based therapies have a higher chance of acceptance in the local communities.
- **Ecological sustainability:** Emphasis on renewable plant materials and traditional methods can make ecological footprint smaller.
- **Rapid Preclinical Screening:** Plants that have been used historically are a priority in pharmacological screening, saving on time and resources.

Example:

Through the utilization of already known medicinal plants used in folk medicine, researchers were able to narrow down their desired compounds to curcumin and 2-hederin, reducing the time and effort required to find compounds with potential anticancer effects and reducing the trial-and-error involved in choosing the desired compound.

4.3. Limitations and Challenges

Integrative approaches have major problems despite the obvious benefits[28]:

- **Standardization:** Results may not be reproducible due to variability in plant species, environmental conditions and preparation methods.
- **Ethical Issues:** There should be fair benefit-sharing, consent and intellectual property when using indigenous knowledge.
- **Regulatory Hurdles:** There are complex regulatory procedures that are involved in the pathway of transitioning preclinical studies to approved therapeutics.
- **Data Integration Problems:** To integrate ethnobotanical data and modern pharmacological data one needs multidisciplinary knowledge and an accurate interpretation.

Table 5: Limitations of Integrative Approaches[29]

Limitation	Description	Implications
Standardization	Variability in plant sources and preparation	Difficult reproducibility in experiments
Ethical Concerns	Fair use of indigenous knowledge	Requires benefit-sharing and informed consent
Regulatory Hurdles	Complex approval processes for new drugs	Delays translation from research to clinic
Data Integration Challenges	Harmonizing traditional and modern scientific data	Risk of misinterpretation or bias

Integrative approaches offer a good avenue to reconcile the discontinuity between traditional knowledge and modern medicine[30]. The incorporation of the ideas of ethnopharmacology with the analytical power of pharmacognosy will enable the researchers to unveil new therapeutic agents in an efficient manner. Although the benefits are improved discovery, cultural relevancy, and sustainability, it is important to overcome limitations like standardization, ethical compliance, and regulatory issues to achieve a successful translation to clinical applications.

5. DISCUSSION

Ethnopharmacology and pharmacognosy integration has come out as an effective method of discovering new therapeutic agents[31]. The traditional knowledge that is documented and rigorously scientifically validated can be used to isolate the bioactive compounds, test their efficacy and safety in animal models and determine their mechanisms of action. An example of this synergy is the case of 2-hederin in Nigella sativa: traditional use guided the choice of the plant, where pharmacognostic techniques, including chromatography, spectroscopy, and in vivo assays

proved its anti-cancer potential. Likewise, Curcuma longa shows how ethnobotanical knowledge can inform the identification of such compounds as curcumin that have been validated pharmacologically.

5.1. Interpretation of Findings

The reviewed articles have in common the assertion of the complementary nature of ethnopharmacology and pharmacognosy in the development of new drug discovery[32]. To begin with, the animal models have been consistently used and have not been dispensable because they have been providing important information on toxicity, efficacy, and the mechanistic pathways and therefore, candidate compounds pass through controlled biological systems before their translations to clinical trials[33]. Second, ethnopharmacological knowledge is a guiding principle, which in fact makes the broad spectrum of natural products smaller by focusing on plants and compounds with known traditional use, which have a better chance of being bioactive in preclinical assays. This saves both time and money as well as improves chances of success of drug development pipelines[34]. Third, the pharmacognostic methods of isolating, structurally characterizing and mechanistically testing bioactive compounds (e.g., 2-hederin) can offer the scientific rigor necessary to substantiate traditional claims and define robust structure-activity relationships[35]. Collectively, these results highlight the value of an inseparable strategy where ethnopharmacology provides guidance, pharmacognosy provides authentication, and preclinical investigations verify therapeutic potential-thus speeding the transformation of natural products in the traditional medicine to modern therapeutics.

5.2. Significance and Implications

The cross-over between these fields is important in a number of ways:

- **Faster Drug Discovery:** The preclinical testing can be accelerated by targeting the bioactive compounds that are proposed by traditional medicine[36].
- **Cultural and Social Relevance:** Indigenous knowledge-based therapies stand a better chance of being accepted by the locals, which will facilitate integration between traditional and modern medicine.
- **Sustainability in Drug Development:** Sustainable Drug Development can be achieved through the use of renewable plant sources and emphasis on traditional remedies with extensive documentation to minimize the ecological impact and sustainable use of natural resources[37].
- **Mechanistic Insights:** Pharmacognostic studies in animals also confirm the efficacy in addition to the revelation of molecular pathways; this leads to targeted therapy.

Besides, the method can be useful in discovering new compounds that can be used as leads in chronic diseases, cancer, inflammatory diseases, and infectious diseases, thus supplementing the world pharmacopeia[38].

5.3. Research Gaps and Future Directions

The integrative approach has a number of gaps and challenges:

1. **Standardization and Reproducibility:** The results of the studies are not reproducible because of variability in plant species, geographic origin, and preparation method. It is

recommended that future studies seek to standardize procedures of ethnobotanical documentation, isolation of compounds and animal testing[39].

2. **Ethical Considerations:** To ethically utilize indigenous knowledge, proper benefit-sharing, informed consent and intellectual property rights have to be considered. There should be clear ethical guidelines that are built together with the local communities.
3. **Limited Translational Data:** Animal-based research is useful to provide the basics, but the translation to clinical application is understudied. To supplement the animal data, future studies ought to consider advanced preclinical models, such as organ-on-chip and 3D tissue cultures[40].
4. **Interdisciplinary Integration:** There should be increased collaborations between ethnobotanists, pharmacologists, chemists and policy makers in order to make the most out of integrative drug discovery.
5. **Database and Knowledge Management:** Systematic ethnopharmacological data with pharmacognostic results could be used to develop predictive models of bioactivity to direct future research more effectively.

6. CONCLUSION

The ethnopharmacology and pharmacognosy interface offer a strong foundation to new therapeutic agents' discovery. The combination of the classical wisdom and the modern scientific approaches will allow the researchers to efficiently find, isolate, and test the bioactive compounds as it happened with alpha-hederin of Nigella sativa and curcumin of Curcuma longa. Preclinical experiments using animals are central to confirming efficacy, safety, and the mechanisms of action, that fill the gap between historical and contemporary pharmacology. This integrative process does not only make it faster to discover new drugs but also makes them culturally relevant, sustainable, and scientifically rigorous. Nonetheless, issues like standardization, ethics, and regulatory barriers have to be overcome to maximize translational potential. Future studies ought to pay attention to the creation of standardized research methodologies, to interdisciplinary research, and to the development of ethical guidelines to guide the ethical use of indigenous knowledge. All in all, it can be concluded that the overlap of these fields of study emphasizes the invaluable nature of natural products in contemporary medicine and suggests a strategic direction in the development of safe and effective culturally sensitive drugs.

REFERENCES

1. Süntar, I. (2020). Importance of ethnopharmacological studies in drug discovery: role of medicinal plants. Phytochemistry Reviews, 19(5), 1199-1209.
2. Leitão, S. G., & de Oliveira, D. R. (2014). The modern pharmacognosy and the ethnopharmacological approach on natural products research. Rev Bras Farm, 24, 97-98.
3. Alamgir, A. N. M. (2017). Origin, definition, scope and area, subject matter, importance, and history of development of pharmacognosy. In Therapeutic Use of Medicinal Plants and Their Extracts: Volume 1: Pharmacognosy (pp. 19-60). Cham: Springer International Publishing.
4. Cahlíková, L., Šafratová, M., Hošťálková, A., Chlebek, J., Hulcová, D., Breiterová, K., &Opletal, L. (2020). Pharmacognosy and its role in the system of profile disciplines in pharmacy. Natural Product Communications, 15(9), 1934578X20945450.

5. Kumar, S., Prasad, A. K., Iyer, S. V., & Vaidya, S. K. (2013). Systematic pharmacognostical, phytochemical and pharmacological review on an ethno medicinal plant, Basella alba L. Journal of Pharmacognosy and Phytotherapy, 5(4), 53-58.
6. Khyade, M. S., &Vaikos, N. P. (2014). Wrightiatinctoria R. Br.-a review on its ethnobotany, pharmacognosy and pharmacological profile. Journal of Coastal Life Medicine, 2(10), 826-840.
7. Singh, A. (2022). A Review of various aspects of the Ethnopharmacological, Phytochemical, Pharmacognostical, and Clinical significance of selected Medicinal plants. Asian Journal of Pharmacy and Technology, 12(4), 349-0.
8. Maiti, R. K., & Singh, V. P. (2019). A review on research advances in ethnobotany and pharmacognosy of some medicinal plants. Farming and Management, 4(1), 45-52.
9. Chaudhary, P. H., &Khadabadi, S. S. (2012). Bombax ceiba Linn.: pharmacognosy, ethnobotany and phyto-pharmacology. Pharmacognosy Communications, 2(3), 2-9.
10. Oko, O. O., Agiang, E. A., &Osim, E. E. (2014). Pharmacognosy of Aspiliaafricana plant: phytochemistry and activities. Bioactive Phytochemicals: Perspectives for Modern Medicine, 2, 383-409.
11. Dhami, N. (2013). Trends in Pharmacognosy: A modern science of natural medicines. Journal of herbal medicine, 3(4), 123-131.
12. Osyntseva, A. (2024). Tuberculosis: pharmacognosy, medicinal plant raw materials, medicinal plants, phytotherapy. SSP Modern Pharmacy and Medicine, 4(1), 1-10.
13. Sadhu, P., Kumari, M., Parmar, G., &Talele, C. (2025). Molecular Pharmacognosy. Pharmacognosy and Phytochemistry: Principles, Techniques, and Clinical Applications, 395-420.
14. Upadhyay, G., & Thakur, P. (2024). Ethnopharmacognosy of Medicinal Plants: Challenges and Biotechnological Advancements. In Ethnopharmacology and OMICS Advances in Medicinal Plants Volume 1: Uncovering Diversity and Ethnopharmacological Aspects (pp. 93-101). Singapore: Springer Nature Singapore.
15. Heinrich, M. (2013). Ethnopharmacology and drug discovery. Elsevier reference module in chemistry, molecular sciences and chemical engineering. Elsevier, Waltham, 1-24.
16. Heinrich, M., Barnes, J., Prieto-Garcia, J., Gibbons, S., & Williamson, E. M. (2017). Fundamentals of Pharmacognosy and Phytotherapy E-Book: Fundamentals of Pharmacognosy and Phytotherapy E-Book. Elsevier Health Sciences.
17. Leonti, M., Casu, L., de Oliveira Martins, D. T., Rodrigues, E., & Benítez, G. (2020). Ecological theories and major hypotheses in ethnobotany: their relevance for ethnopharmacology and pharmacognosy in the context of historical data. RevistaBrasileira de Farmacognosia, 30(4), 451-466.
18. Balogun, F. O., Ashafa, A. O. T., Sabiu, S., Ajao, A. A. N., Perumal, C. P., & Kazeem, M. I. (2019). Pharmacognosy: Importance and. Pharmacognosy: Medicinal Plants, 289.
19. Delgoda, R. (2016). Pharmacognosy: Fundamentals, applications and strategies. Academic Press.
20. Pandey, A., & Tripathi, S. (2014). A review on pharmacognosy, pre-phytochemistry and pharmacological analysis of Tridaxprocumbens. PharmaTutor, 2(4), 78-86.

21. Patwardhan, B., &Chaguturu, R. (2016). Innovative approaches in drug discovery: ethnopharmacology, systems biology and holistic targeting.
22. SARKAR, S., & SRIVASTAVA, V. (2020). Ethnopharmacology and drug development. International Journal of Pharmaceutical Research (09752366), 12(4).
23. Egbuna, C., Nadia, S., &Jabeen, N. S. (2018). Pharmacognosy and prehistoric uses of medicinal plants. In Phytochemistry (pp. 3-16). Apple Academic Press.
24. Arora, D., Rani, A., & Sharma, A. (2013). A review on phytochemistry and ethnopharmacological aspects of genus Calendula. Pharmacognosy reviews, 7(14), 179.
25. Singh, A. (Ed.). (2011). Herbalism, phytochemistry and ethnopharmacology. CRC Press.
26. Reyes-García, V. (2010). The relevance of traditional knowledge systems for ethnopharmacological research: theoretical and methodological contributions. Journal of ethnobiology and ethnomedicine, 6(1), 32.
27. Leonti, M., Stafford, G. I., Dal Cero, M., Cabras, S., Castellanos, M. E., Casu, L., &Weckerle, C. S. (2017). Reverse ethnopharmacology and drug discovery. Journal of ethnopharmacology, 198, 417-431.
28. Bokov, D. O., Krasikova, M. K., Sergunova, E. V., Bobkova, N. V., Bondar, A. A., Marakhova, A. I., ... &Moiseev, D. V. (2020). Pharmacognostic, phytochemical and ethnopharmacological potential of Cyclamen coum Mill. Pharmacognosy Journal, 12(1).
29. Ansari, M. K. A., Iqbal, M., Chaachouay, N., Ansari, A. A., & Owens, G. (2023). The concept and status of medicinal and aromatic plants: history, pharmacognosy, ecology, and conservation. In Plants as medicine and aromatics (pp. 129-144). CRC Press.
30. Hohmann, J., Echeverria, J., & Yen, H. R. (2022). ethnopharmacology: 2021. Insights in Ethnopharmacology: 2021, 5.
31. Lattibeaudiere, K., & Newman, S. (2024). A Review of the Multifaceted Plant, Desmodiumcanum: The Traditional and Ethnopharmacological Applications and its Potential Use in Medicine. Pharmacognosy Reviews, 18(35).
32. Moore, N., Hamza, N., Berke, B., & Umar, A. (2017). News from Tartary: an ethnopharmacological approach to drug and therapeutic discovery. British Journal of Clinical Pharmacology, 83(1), 33-37.
33. Cock, I. (2013). The phytochemistry and chemotherapeutic potential of Tasmannialanceolata (Tasmanian pepper): A review. Pharmacognosy Communications, 3(4), 1-13.
34. Egbuna, C., Kumar, S., Ifemeje, J. C., &Kurhekar, J. V. (Eds.). (2018). Phytochemistry: Volume 2: Pharmacognosy, Nanomedicine, and Contemporary Issues. CRC Press.
35. Dey, P., & Chaudhuri, T. K. (2014). Pharmacological aspects of Nerium indicum Mill: a comprehensive review. Pharmacognosy reviews, 8(16), 156.
36. Ali, S. I., Gopalakrishnan, B., &Venkatesalu, V. (2017). Pharmacognosy, phytochemistry and pharmacological properties of Achillea millefolium L.: a review. Phytotherapy research, 31(8), 1140-1161.
37. Sarker, S. D. (2012). Pharmacognosy in modern pharmacy curricula. Pharmacognosy magazine, 8(30), 91.
38. Lardos, A. (2015). Historical approaches in ethnopharmacology. Ethnopharmacology, 333-342.

39. Patel, M. H., Desai, B., Jha, S., Patel, D., Mehta, A., & Garde, Y. (2023). Phytochemical, pharmacognosy and ethnobotanical importance of the FicusvirensAiton. Pharma Innov. J, 12, 4017-4021.

40. Tewari, D., Stankiewicz, A. M., Mocan, A., Sah, A. N., Tzvetkov, N. T., Huminiecki, L., ... &Atanasov, A. G. (2018). Ethnopharmacological approaches for dementia therapy and significance of natural products and herbal drugs. Frontiers in aging neuroscience, 10, 3.